HUTCHMED Reports the NMPA’s Acceptance of sNDA for Savolitinib to Treat NSCLC

Share this

HUTCHMED Reports the NMPA’s Acceptance of sNDA for Savolitinib to Treat NSCLC


  • The NMPA has accepted the company’s sNDA of savolitinib for treatment-naïve or previously treated locally advanced or metastatic MET Exon 14 NSCLC patients
  • The sNDA was supported by the P-IIIb clinical evaluation to assess the safety, effectiveness & tolerability of savolitinib to treat locally advanced or metastatic NSCLC patients having MET Exon 14 mutations
  • The study showed an ORR of 62.1%, DCR of 92%, mDoR of 12.5mos. & mPFS of 13.7mos. with mOS not attained at a median follow-up of 20.8mos. in treatment-naïve patients while an ORR of 39.2%, DCR of 92.4%, mDoR of 11.1mos. & mPFS of 11mos. with mOS not reached at a median follow-up of 12.5mos. was seen in previously treated patients


Related News:- HUTCHMED and AstraZeneca Report P-II (SAVANNAH) Trial Results of Tagrisso + Savolitinib for EGFR-Mutated NSCLC

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions